Latest Clinical Data News

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

Nexsen Limited is advancing its rapid Group B Streptococcus test, StrepSure®, with a clear FDA submission timeline and early market entries across Asia-Pacific and emerging regions.

Clarity Pharmaceuticals has signed a significant manufacturing supply agreement with Theragenics to produce copper-64, a key isotope for its upcoming prostate cancer diagnostic, Cu-SAR-bisPSMA. This deal strengthens Clarity’s US supply network ahead of anticipated FDA approval and commercial launch.

Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.

Enlitic has secured a $1.5 million contract to migrate over 71 million clinical files for Penn Medicine Doylestown Health, reinforcing its foothold in the US healthcare IT sector.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.